^
    Back
    Association details:
    Biomarker:RET amplification + TMB-H + PD-L1 expression
    Cancer:Hepatocellular Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    The Oncologist
    Title:

    Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression

    Excerpt:
    A patient with metastatic hepatocellular carcinoma (HCC) harboring RET amplification, high tumor mutational burden, and positive programmed death-ligand 1 expression responded well to the combination of cabozantinib and nivolumab therapy with progression-free survival of longer than 25 months.
    DOI:
    10.1634/theoncologist.2019-0563